Lucía Cortejoso1, Xandra García-González1, María I García1, Pilar García-Alfonso2, María Sanjurjo1, Luis A López-Fernández1. 1. Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain. 2. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain.
Abstract
AIM: To compare the cost of screening for three mutations in the dihydropyrimidine dehydrogenase gene and the costs of treating severe fluoropyrimidine-induced neutropenia. MATERIALS & METHODS: The polymorphisms rs3918290 (DPYD*2A), rs67376798 (DPYD 2846A>T) and rs55886062 (1679T>G, DPYD*13) were genotyped using real-time PCR, TaqMan probes and a rapid cell lysis to provide PCR-ready DNA. RESULTS: We found that genotyping 1000 patients in our center cost €6400 and that the mean cost of treating severe neutropenia was €3044. Therefore, if severe fluoropyrimidine-induced neutropenia is reduced by genotyping the three DPYD variations in at least 2.21 cases per 1000 treated patients, then DPYD genotyping will prove cost effective. CONCLUSION: We demonstrated that real-time DPYD genotyping using TaqMan probes is cost effective in all fluoropyrimidine-based treatments.
AIM: To compare the cost of screening for three mutations in the dihydropyrimidine dehydrogenase gene and the costs of treating severe fluoropyrimidine-induced neutropenia. MATERIALS & METHODS: The polymorphisms rs3918290 (DPYD*2A), rs67376798 (DPYD 2846A>T) and rs55886062 (1679T>G, DPYD*13) were genotyped using real-time PCR, TaqMan probes and a rapid cell lysis to provide PCR-ready DNA. RESULTS: We found that genotyping 1000 patients in our center cost €6400 and that the mean cost of treating severe neutropenia was €3044. Therefore, if severe fluoropyrimidine-induced neutropenia is reduced by genotyping the three DPYD variations in at least 2.21 cases per 1000 treated patients, then DPYD genotyping will prove cost effective. CONCLUSION: We demonstrated that real-time DPYD genotyping using TaqMan probes is cost effective in all fluoropyrimidine-based treatments.
Entities:
Keywords:
5-fluorouracil; capecitabine; drug adverse reactions
Authors: Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle Journal: Annu Rev Genomics Hum Genet Date: 2022-05-10 Impact factor: 9.340
Authors: Apostolos Tsiachristas; Grant Vallance; Rositsa Koleva-Kolarova; Harriet Taylor; Luke Solomons; Giovanni Rizzo; Catherine Chaytor; Junel Miah; Sarah Wordsworth; A Bassim Hassan Journal: BMC Cancer Date: 2022-04-26 Impact factor: 4.638
Authors: A Ruzzo; F Graziano; Fabio Galli; Francesca Galli; E Rulli; S Lonardi; M Ronzoni; B Massidda; V Zagonel; N Pella; C Mucciarini; R Labianca; M T Ionta; I Bagaloni; E Veltri; P Sozzi; S Barni; V Ricci; L Foltran; M Nicolini; E Biondi; A Bramati; D Turci; S Lazzarelli; C Verusio; F Bergamo; A Sobrero; L Frontini; M Menghi; M Magnani Journal: Br J Cancer Date: 2017-08-24 Impact factor: 7.640
Authors: Xandra García-González; Sara López-Tarruella; María Isabel García; Eva González-Haba; Carolina Blanco; Sara Salvador-Martin; Yolanda Jerez; Fabienne Thomas; María Jarama; María Sanjurjo Sáez; Miguel Martín; Luis Andrés López-Fernández Journal: Cancer Manag Res Date: 2018-10-11 Impact factor: 3.989
Authors: Paula Soria-Chacartegui; Gonzalo Villapalos-García; Luis A López-Fernández; Marcos Navares-Gómez; Gina Mejía-Abril; Francisco Abad-Santos; Pablo Zubiaur Journal: Pharmaceutics Date: 2021-11-29 Impact factor: 6.321